Search our Database of Scientific Publications and Authors

I’m looking for a
    Signal peptide increases the efficacy of angiogenic gene transfer for treatment of myocardial ischemia.
    Hum Gene Ther 2005 Sep;16(9):1058-64
    Veterans Administration San Diego Healthcare System, and Department of Medicine, University of California San Diego, La Jolla, CA 92161, USA.
    We have previously shown that intracoronary delivery of recombinant adenoviruses encoding angiogenic proteins that contain signal peptides (fibroblast growth factor-4 and fibroblast growth factor-5) ameliorate myocardial ischemia. In the present paper, we test the hypothesis that the presence of the signal peptide is an important element in the favorable effects that transgene expression has on regional flow and function in an animal model of myocardial ischemia. We performed intracoronary delivery of two different recombinant adenoviruses encoding a fibroblast growth factor-2 variant, one with a signal peptide, FGF-2LI(+sp), and one without a signal peptide, FGF-2LI(-sp). In a model of stress-induced myocardial ischemia, intracoronary injection of these recombinants resulted in mRNA and protein expression of the transferred gene. Two weeks after gene transfer, regional abnormalities in stress-induced function and blood flow were improved after delivery of FGF-2LI containing the signal peptide. In the absence of the signal peptide, perfusion was not improved, and function was improved to a lesser degree than with FGF-2LI containing the signal peptide. These studies indicate that the presence of a signal peptide increases the efficacy of treatment and may reduce the required recombinant adenovirus dose for a given effect, and thereby provide an important safety margin for clinical application.

    Similar Publications

    Increased regional function and perfusion after intracoronary delivery of adenovirus encoding fibroblast growth factor 4: report of preclinical data.
    Hum Gene Ther 2004 Jun;15(6):574-87
    VA San Diego Healthcare System (111-A), 3350 La Jolla Village Drive, San Diego, CA 92161, USA.
    This paper reports the preclinical data that were used to support clinical trials of intracoronary delivery of a replication-incompetent human adenovirus-5 vector encoding human fibroblast growth factor 4 (Ad5FGF4). Using stress-induced myocardial ischemia in pigs, intracoronary injection of Ad5FGF4 resulted in mRNA and protein expression of the transferred gene. Two weeks after gene transfer, regional stress-induced dysfunction and perfusion were ameliorated and improved function persisted for at least 12 weeks. Read More
    Comparison of protein with DNA therapy for chronic myocardial ischemia using fibroblast growth factor-2.
    Eur J Cardiothorac Surg 2002 Dec;22(6):957-64
    Department of Cardiovascular Surgery, Albert-Ludwigs-University Freiburg, Freiburg, Germany.
    Objective: Treatment of coronary disease by growth factors has become an increasingly used strategy for otherwise untreatable patients and is subject to a number of clinical studies. The aim is to stimulate the development of a sufficient collateral circulation and hereby to rescue cardiac function. The objective of our study was to compare the effectiveness of fibroblast growth factor-2 (FGF-2) as protein and as naked plasmid DNA in a porcine model of chronic myocardial ischemia. Read More
    Intracoronary delivery of an adenovirus encoding fibroblast growth factor-4 in myocardial ischemia: effect of serum antibodies and previous exposure to adenovirus.
    Hum Gene Ther 2006 Feb;17(2):230-8
    Collateral Therapeutics Inc., San Diego, CA 92130, USA.
    The presence of anti-adenoviral serotype 5 (Ad5) antibodies may limit the efficacy of Ad5-mediated gene transfer. We therefore tested the hypothesis that intracoronary delivery of an adenovirus encoding human fibroblast growth factor type 4 (Ad5.FGF4) would improve regional myocardial function in an animal model of ischemia when high antibody levels preexist or after a prior intracoronary dose of Ad5. Read More
    Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart.
    Nat Med 1996 May;2(5):534-9
    Department of Medicine, Veteran's Affairs Medical Center-San Diego, California, USA.
    Increased coronary blood vessel development could potentially benefit patients with ischemic heart disease. In a model of stress-induced myocardial ischemia, intracoronary injection of a recombinant adenovirus expressing human fibroblast growth factor-5 (FGF-5) resulted in messenger RNA and protein expression of the transferred gene. Two weeks after gene transfer, regional abnormalities in stress-induced function and blood flow were improved, effects that persisted for 12 weeks. Read More